Akeso Inc. Announces Positive Results from Global Phase III HARMONi Trial of Ivonescimab, Demonstrating Improved Overall Survival in Lung Cancer Patients
Akeso, Inc. announced positive results from the global Phase III HARMONi trial of ivonescimab, showing improved overall survival in lung cancer patients. The trial revealed a hazard ratio of 0.78 and a median overall survival of 17.0 months for patients receiving ivonescimab, compared to 14.0 months for those on placebo. The findings indicate consistent benefits across subgroups. Additionally, the HARMONi-A study in China has reached its overall survival clinical endpoint, with results to be shared at future conferences.
Akeso, Inc. has announced updated results from the global Phase III HARMONi clinical trial of ivonescimab, a PD-1/VEGF bispecific antibody. This update, shared by Summit Therapeutics, Akeso’s global partner, during the 2025 World Conference on Lung Cancer, highlights longer-term follow-up data of western patients showing an improving trend in overall survival (OS). The analysis revealed a hazard ratio of 0.78 with a nominal p-value of 0.0332. The median OS for western patients receiving ivonescimab was 17.0 months compared to 14.0 months for those receiving placebo. These findings demonstrate consistent benefits across various subgroups. Akeso has also announced that the HARMONi-A study conducted in China has reached its OS clinical endpoint, with results to be presented at future academic conferences. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN67362) on September 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
